FibroGen is Third Bay Area Biomed to Hike IPO

Home/Financial/FibroGen is Third Bay Area Biomed to Hike IPO

FibroGen is Third Bay Area Biomed to Hike IPO

From  at Biotech SF/SF Business Times:

“Drug developer FibroGen has increased by 24 percent the amount it hopes to raise by going public, becoming the third Bay Area biotech-health company this week to increase their IPO targets.

The San Francisco company, led by CEO Thomas Neff, said in a Securities and Exchange Commission filing that it hopes to raise up to $155 million, up from the $125 million target it announced when it first disclosed its plans earlier this month.

FibroGen said it plans to sell 7.1 million shares for between $16 and $19 apiece, and the rest of the money would come if underwriters buy up all of the extra shares allotted to them.”

Full report

November 3rd, 2014|

Leave A Comment

X